Biography
Dr. Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely used tools for analyzing cancer genomes. Dr. Getz is a Professor of Pathology at Harvard Medical School. He is the Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology, and is an Institute Member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. He has published over 400 papers inprominentjournals describing new methodologies to study cancer genomesthat haveidentified new genes and pathways involved in different tumortypes, mutational signatures, and tumor evolution.

Biography
As Chief Scientific Officer for Clear Labs, Dr. Khaksar leads the vision and strategy for talented teams of dedicated scientists who make life healthier through the application of genomics and intelligent analytics. From a leadership perspective, he prioritize team culture and empower my team members to maximize their talents and push the bounds of what's possible. As a scientist and researcher, Dr. Khaksar have deep insights into the world of health, biotechnology, and next generation sequencing, and Ihe continue to contribute to the world of academia as an adjunct faculty member at Rutgers University. Dr. Khaksar like to leave a legacybyraising the quality of life and health of the world's population. Throughhis work at Clear Labs, they have made a huge impact on foodsafety. Dr. Khaksar aim to expand that impact by using my skills toimprove clinicaland pharmaceutical genomics and their effectiveness inpublic health.

Sequencing Technologies Showcase:
Clear Labs
Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applicationstodeliver increased clarity.

Biography
James an Associate Professor of Biomedical Data Science and, by courtesy, of Computer Science and Electrical Engineering at Stanford University. James works on making AI more reliable, human-compatible and statistically rigorous, and am especially interested in applications in human disease and health. James received his Ph. D from Harvard in 2014, and was at one time a member of Microsoft Research, a Gates Scholar at Cambridge and a Simons fellow at U. C. Berkeley. James joined Stanford in 2016 and am excited to also be a Chan-Zuckerberg Investigator. We are also a part of the Stanford AI Lab. His research is supported by two Chan-Zuckerberg Biohub Investigator Awards, the Sloan Fellowship, the NSF CAREER Award, a Top Ten Clinical Achievement Award and faculty awards from Google, Adobe and Amazon.

Biography
Dr. Michael Kahana is CEO and co-founder of Nia Therapeutics, which is developing an AI-guided closed-loop neurostimulation therapy for memory loss. During his 30-year academic career, Kahana published more than 200 scientific articles and won numerous awards for his pioneering research on the neural basis of human memory and for his contributions ot memory theory.

Biography
Ari is Co-Founder and CSO at Weave Bio. Weaves native-AI regulatory platform helps life science companies to weave together data and documentation for all regulatory submissions, from pre-IND to NDABLA, directly from the source data and studies. Previously, Ari was the first Chief Analytics Officer at Memorial Sloan Kettering Cancer Center (MSK) where he drove pioneering efforts using clinical data to analyze patient outcomes. Aris team at MSK developed the first operational AI model to match patients to clinical trials. While at MSK, Ari also contributed to the creation of startups like Flatiron Health and Paige AI. In 2019, Ari cofounded Daat. AI which was acquired by Tempus AI, where Ari served as SVP of RWD.

Biography
Dina Katabi is the Thuan and Nicole Pham Professor of Electrical Engineering and Computer Science at MIT, and the President and CEO of Emerald Innovations inc. Katabi isa recipient of the Mac Arthur Fellowship, and a member of the National Academy of Engineering, the National Academy of Sciences, and the American Academy of Arts and Sciences. Her research focuses on innovations indigital health, wireless biosensing, and machine learning.

Biography
Dr. Nath is a cancer biologist with expertise in both experimental andcomputational biology. At City of Hope, Dr. Nath leads a collaborative research team that investigates the potential of A IML in enhancing cancer patient outcomes. Through the integration of bioinformatics and A IML tools, his research aims tounravel the underlying mechanisms of tumor progression and establishcutting-edge biomarkers for improving the clinical outcomes of patientswith cancer. His research employs multi-omics approaches to identify the drivers of tumor evolutionand the subsequent development of drug resistance. Dr. Nath aspires totranslate research findings into clinical impact, notably contributing to upcoming clinical trials in lung and breast cancer that will implement novel AI-guided biomarkers. Dr. Nath currently is aprincipal investigator (PI) of an A RPA-H grant, an NIH U01 grant, a PHASE ONE foundation grant, a JKTG foundation grant, andco-investigator of an A RPA-H and California Institute for Regenerative Medicine (CIRM) grant.

Biography
Vinod Khosla is an entrepreneur, investor, and technology fan. He is the founder of Khosla Ventures, focused on impactful technology investments in software, AI, robotics, 3Dprinting, healthcare and more. Mr. Khosla was a co-founder of Daisy systems and foundingCEO of Sun Microsystems where he pioneered open systems and commercial RIS Cprocessors. One of Mr. Khoslas greatest passions is being a mentor to entrepreneurs, assisting entrepreneurs and helping them build technology-basedbusinesses. Mr. Khosla isdriven by the desire to make a positive impact through technology to reinvent societalinfrastructure and multiply resources. He is also passionate about Social Entrepreneurship. Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, a Master's in Biomedical Engineering from Carnegie Mellon University and an MBA from the Stanford Graduate School of Business.

Biography
Alex's focus at Khosla Ventures is in biotechnology, healthcare, data science, and A IML.

Biography
Greg Brockman is the President and Co-Founder of OpenAI, where he currently leads the companys Scaling organizationfocused on expanding the technical infrastructure and systems needed to support OpenAIs rapid growth and increasingly capable models. He has played a central role in shaping OpenAIs mission and in bringing transformative technologies like ChatGPT, DALLE, and Codex to millions of people and businesses around the world. Before OpenAI, Greg was the CTO of Stripe, where he built and led the engineering team during a period of rapid scale. He studied mathematics at Harvard and computer science at MIT before leaving to pursue a career at the forefront of technology. Greg is a technologist and builder, deeply invested in ensuring artificial general intelligence is developed safely and benefits all of humanity. He regularly speaks on the future of AI, responsible deployment, and the infrastructure powering the next generation of intelligent tools.

Talk

Biography
Massa Shoura is the CEO and CSO of Phinomics, a company unlocking circular DNA; a master driver of oncogenesis and drug resistance that remained invisible for decades. Phinomics' proprietary technology captures circular DNA at 100× higher resolution, integrating it with transcriptomics, epigenetics, and proteomics through ML/AI to discover transformative cancer therapies targeting the once-undruggable. With dual Ph Ds in Molecular Biology and Biomedical Engineering, Massa brings over a decade of expertise in DNA topology, biophysics, and genomics. During her postdoctoral fellowship at Stanford University in Nobel Laureate Dr. Andrew Fire's lab, she developed groundbreaking tools for isolating and characterizing circular DNA, earning prestigious fellowships including the Arnold O. Beckman Fellowship and securing two granted patents. As a Forbeck Scholar, she advanced cancer genomics by uncovering the role of oncogenic circular DNA amplification. She also spearheaded the sequencing and publication of Pfizer and Moderna COVID-19 vaccine mRNAs, showcasing her commitment to global health. At Phinomics, Massa leads the development of first-in-class precision oncology therapies by building and mining the only virtual cell model constructed from matched normal-cancer datasets that integrate circular DNA with orthogonal multi-omic data, revealing previously hidden druggable targets and therapeutic strategies.

Biography
Omar has decades of experience designing global cloud platforms pioneering the use of collaborative feedback networks to solve challenging information extraction problems. He is the Principal Architect of precisionFDA. gov, the FDA cloud platform that is transforming the regulatory research and review process for precision drugs and devices. Prior to DN Anexus, Omar managed operations for the A WS Elastic Compute Cloud when single regions were topping the one-million server mark. Previously, he led platforms for a Twitter search engine at Topsy Labs, and crowd-sourced messaging security at Cloudmark. Omar received his Bachelor of Science in Chemistry from UC Berkeley.

Biography
Greg Brockman is the President and Co-Founder of OpenAI, where he currently leads the company’s Scaling organization—focused on expanding the technical infrastructure and systems needed to support OpenAI’s rapid growth and increasingly capable models. He has played a central role in shaping OpenAI’s mission and in bringing transformative technologies like ChatGPT, DALL·E, and Codex to millions of people and businesses around the world. Before OpenAI, Greg was the CTO of Stripe, where he built and led the engineering team during a period of rapid scale. He studied mathematics at Harvard and computer science at MIT before leaving to pursue a career at the forefront of technology. Greg is a technologist and builder, deeply invested in ensuring artificial general intelligence is developed safely and benefits all of humanity. He regularly speaks on the future of AI, responsible deployment, and the infrastructure powering the next generation of intelligent tools.

Biography
Vinod Khosla is an entrepreneur, investor, and technology fan. He is the founder of Khosla Ventures, focused on impactful technology investments in software, AI, robotics, 3Dprinting, healthcare and more. Mr. Khosla was a co-founder of Daisy systems and foundingCEO of Sun Microsystems where he pioneered open systems and commercial RIS Cprocessors. One of Mr. Khoslas greatest passions is being a mentor to entrepreneurs, assisting entrepreneurs and helping them build technology-basedbusinesses. Mr. Khosla isdriven by the desire to make a positive impact through technology to reinvent societalinfrastructure and multiply resources. He is also passionate about Social Entrepreneurship. Vinod holds a Bachelor of Technology in Electrical Engineering from IIT, New Delhi, a Master's in Biomedical Engineering from Carnegie Mellon University and an MBA from the Stanford Graduate School of Business.

Biography
A Silicon Valley icon, technology entrepreneur, and philanthropist for more than four decades, Steve Wozniak has helped shape the computing industry through his design of Apples first line of productsthe Apple I and IIand his influence on the Macintosh. In 1976, Wozniak and Steve Jobs co-founded Apple Computer Inc. with Wozniaks Apple I, followed by the Apple II, which helped launch the personal computer revolution. He is listed as the sole inventor on four Apple patents. After completing his degree in electrical engineering and computer science at UC Berkeley, Wozniak founded Unuson, producer of the US Festivalsa landmark fusion of technology and music. His achievements have been recognized with the National Medal of Technology from President Ronald Reagan, induction into the National Inventors Hall of Fame, and the Heinz Award for Technology, the Economy and Employment. A committed advocate for education and innovation, Wozniak has championed technology access in schools and supported institutions such as the Electronic Frontier Foundation, the Tech Museum of Innovation, and the Childrens Discovery Museum of San Jose. He is the author of the New York Times best-selling autobiography i Woz and continues to advance technology education as co-founder of Woz U and Efforce, a blockchain-based sustainability platform.

Biography
Dr. Musso has a background in molecular genetics (PhD), and didpost-doctoral work at Harvard Medical School and Brigham and Women's Hospital on computational and developmental biology. He spent time at astart-up working on real-time machine learning, before joining with othersto start Bio Symetrics with the aim of tackling the specific challenges ofworking with biomedical data. He was named one of the top 100 leaders in AI and drug discovery, has authored over 30 peer reviewed publications on AIM Land biology.

Talk
AI models are accelerating target and compound discovery, but translation remains a bottleneck. We present a closed-loop platform integrating predictive AI with high-throughput in vivo validation using disease models relevant to neurological disease. Case studies demonstrate how this approach improves hit prioritization, enhances biological relevance, and increases success rates in drug development.

Biography
Dr. Georgescu spearheads Vivodyne's vision of reshaping therapeutics development. The loss of translation between animal studies and human trials compelled him to co-found Vivodyne in 2020 and create an entirely new platform from the ground up. With a Ph. D. from Dr. Huh's esteemed organ-chip research group at the University of Pennsylvania, his expertise lies in human-tissue engineering, robotics, and machine learning. His prior achievements include sending lab-grown tissues with NASA to space and developing DNA synthesis chips that remain industry staples to this day.

Biography
Harlan Robins is a Co Founder of Adaptive Biotechnologies, a commercialstage biotech company that aims to translate the genetics of the adaptiveimmune system into clinical products to diagnose and treat disease. Priorto cofoundingconfounding Adaptive, Harlan served in various roles at the Fred Hutchinson Cancer Research Center (FHCRC) in the Computational Biology Program, including Assistant Faculty Member, Associate, and Full Member and Head of the program. Interested in the mathematics behind genetics andobserving the potential utility of high level mathematics to study problemsin the biological sciences, Harlan took a postdoctoral appointment at the Institute for Advance Study in Princeton under famed biologist Dr. Arnold Levine. With Dr. Levine, he concentrated on developing bioinformaticalgorithms for micro RNA targets and bacterial genome analysis, a precursorto his faculty appointment at FHCRC in the Computational Biology Group, Public Health Sciences and Human Biology Divisions.

Biography
Vitalay Fomin, Ph. D., CEO of Numenos AI, is an award-winning data scientist at Roche Genentech specializing in biomarker and reverse translation drug discovery

Talk
We developed a novel foundation model that is biologically awarecapable of using single arm trials to identify optimal indication, patient population and drug combination and optimizes each asset for maximal clinical trial success

Biography
Dr. Amar Das has three decades of experience in advancing clinical researchthrough data science and AI. At Guardant Health, he leads a team thatgenerates real world evidence for blood-based testing in precision oncologyand cancer screening. Prior to Guardant Health, Dr. Das was on the facultyat Stanford and Dartmouth. As Director of Biomedical Informatics at Dartmouth, he co-founded the Department of Biomedical Data Science, thefirst department focused on this discipline. Following his career inacademia, he served as Director of Healthcare Effectiveness Research at IB Mand Director of Real World Data Analytics and Innovation at MerckMSD. Dr. Das has received multiple professional and research awards, and is a Fellowof the American College of Medical Informatics. Dr. Das received his MD and PhD in Biomedical Informatics from Stanford and completed his residency andpostdoctoral fellowship in Clinical Epidemiology at Columbia New York Presbyterian.

Biography
Watsons current work focuses on AI-driven biomolecular design, creatingpredictive peptides and receptor-targeting ligands that are engineered toprecisely deliver nanoparticles, gene-editing tools, drugs, and nucleicacids to specific cells and tissues. This approach aims to enhancetherapeutic specificity, reduce toxicity, and accelerate the development ofcurative and preventative delivery of therapeutics. Previously, whileresearching at Rensselaer Polytechnic Institute, he developed gene-editingdelivery platforms for guided nucleases like CRISPR and TALEN. Today, heapplies AI and predictive physics to rapidly generate and evaluate noveltargeting agents, mapping uncharted receptor-ligand relationships as anenabling technology for biopharmaceutical delivery systems. With over 80pending global patents (22 approved, 6 allowed), Watsons work pioneeredintegrating cell surface transcriptomics, predictive targeting liganddesign, and drug and gene delivery systems. He and his team aim totransform how we approach the worlds most challenging diseases, advancingthe frontier of precision therapeutics and diagnostically-responsivemedicine.

Biography
Colin Hill is a trailblazer in applying causal AI to precision medicine. Aitia, the company he co-founded and leads, has built a powerful Digital Twin discovery and drug development platform, with a current focus on neurodegenerative diseases and oncology. He serves on the boards of Fulcrum Therapeutics (NASDAQ: FULC, a rare genetic disease company, Centrexion Therapeutics, a non-opioid pain therapeutics company, and the Critical Path Institute, which fosters collaborations between scientific and regulatory bodies. He previously served on the boards of mobile health company Biotelemetry Inc., CRO PPD Inc., and sickle cell disease company Aes Rx. In 2004, Colin was named to MIT Technology Reviews TR100 list of the top 100 innovators in the world under the age of 35. He has appeared in publications and television programs including The Wall Street Journal, CNBC Morning Call Squawk Box, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.

Talk
The biggest obstacle to realization of precision medicine is poor knowledge of the complex biological circuitry underlying human health and disease. The convergence of raw computational power, multiomic and clinical data, and causal AI has led to Gemini Digital Twins, in silico circuitry models of virtually any disease (we will discuss Huntington's and prostate cancer).

Biography
Ron Alfa is a physician scientist at the forefront of leveraging technology to tackle unmet therapeutic needs in medicine. He is Co-Founder and CEO of NOETIK, a next generation precision oncology company using multimodal foundation models pre-trained on large-scale human tumor data to discover cancer therapeutics. Prior to founding Noetik, Ron was Senior Vice President, Head of Research and acting-CSO at Recursion, where he led the companys scientific organizations and portfolio strategy. At Recursion, he led portfolio and platform builds across rare disease, neuroscience, oncology, and immunology, and was responsible for advancing multiple therapeutic programs from discovery to clinical development. Ron holds an MD and PhD from Stanford University School of Medicine, where he completed his doctoral work in Neuroscience, and has a MA in History of Medicine from UCL.

Talk
Foundation models for human biology

Biography
Lisa Gurry is the Chief Business Officer at Gene Dx, where she is leading the company through its next phase of growthadvancing data and information services across biopharma, health systems, and other partnersto accelerate the future of precision medicine. In this role, Lisa drives Gene Dxs strategic business operations, partnerships, and data strategy, unlocking the full potential of Gene Dx Infinity, the largest rare disease dataset. She also oversees marketing and communications. With deep expertise at the intersection of healthcare, technology, and data, Lisa has a proven track record of turning bold ideas into scaled businesses. She co-founded Truveta, serving as Chief Growth Officer, Chief Marketing Officer, and Chief Operating Officer. Earlier in her career, Lisa spent more than 20 years at Microsoft.

Talk
Powered by AI and millions of genomes linked to deep longitudinal phenotypic data, GeneDx delivers unparalleled rare-disease intelligence. This session will share how GeneDx partners with biopharma to turn genomic data into actionable solutionsaccelerating discovery and clinical trials, and advancing the next era of precision medicine.

Biography
Dr. Shivaani Kummar is Associate CEO and interim Director, Knight Cancer Institute, Endowed Professor and Division Chief of Hematology and Medical Oncology, and co-Director of the Center of Experimental Therapeutics, Oregon Health Science University, Portland, Oregon, USA. Prior to joining OHSU in 2020, she was on faculty at Yale University Cancer Center, served as Head of Early Clinical Trials Development Office of the Director, Division of Cancer Treatment and Diagnosis, NCI, and was Professor and Director of the Phase 1 Clinical Research Program and Translational Oncology Program at Stanford University, California. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel agents for further clinical investigation. She has authored over 180 peer reviewed publications, 9 book chapters, and co-edited a book. She is the co-founder of PATHOMIQ, a company that has developed an AI platform to predict response to treatment.

Biography
Alex's focus at Khosla Ventures is in biotechnology, healthcare, data science, and A IML.

Biography
Marc Tessier-Lavigne is co-founder, ChairmanCEO of Xaira Therapeutics. Previously, he held executive positions at Genentech, where he was chief scientific officer, and inacademia, where he served as president of The Rockefeller University and of Stanford University, where he remains professor of Biology. He also served previously on thefaculty of the University of California, San Francisco, and was an investigator with the Howard Hughes Medical Institute. A Rhodes Scholar, Dr. Tessier-Lavigne has been aleader in understanding mechanisms that direct brain wiring. He has received numerousscientific awards, including the 2020 Gruber Neuroscience Prize, and has been electedto multiple scientific societies, including the US National Academy of Sciences and US National Academy of Medicine; he is also an Officer of the Order of Canada. Dr. Tessier-Lavigne has co-founded two neuroscience startups, Renovis and Denali, and served on the boards of Agios, Regeneron, Pfizer, Juno and Denali.

Biography
Dr. Liat Dassa is a product leader and a scientist at CytoReason, a leading biological intelligence company that builds computational disease models for biopharma R&D. Liat works at the intersection of product, business, and data, working closely with leadership to translate product vision into actionable priorities. She’s experienced with leading the product data strategy, including identification of high-value multi-omics data, external partnerships, and integration into ML-based product capabilities to drive clinical outcomes. Liat has led multidisciplinary teams across immunology, bioinformatics, and data management to turn computational disease models into products that scientists trust and adopt. With a strong academic background in immunology, she brings a practical perspective on how AI can be embedded into biotech R&D environments to drive real-world clinical impact. She has previously spoken at PMWC on behalf of CytoReason and is passionate about applying data-driven approaches that support confident decision-making, accelerate discovery, and improve patient outcomes.

Talk
CytoReason's computational disease models draw on molecular and clinical data to capture disease biology. This talk showcases how pharma R&D teams leverage CytoReason’s AI technology to prioritize targets and indications, and to make faster, more accurate decisions at critical inflection points.

Biography
Sanoj Punnen, MD, MAS, completed his medical school at Queens University and urology residency at the University of Toronto in Canada. He then completed a uro-oncology fellowship and Masters in Clinical Research at the University of California, San Francisco. He is board-certified in both urology and uro-oncology. His primary research interest is in localized prostate cancer. Specifically, his work has evaluated imaging, molecular, and genomic markers that play a role in prostate cancer diagnosis and prognosis. He is also involved in outcomes and health service research on trends in the incidence and management of prostate cancer.

Biography
Dr Mark E. Burkard, MD, PhD is the Director, UI Holden Comprehensive Cancer Center. He is also Professor and Associate Dean for Cancer Research in the Carver College of Medicine and C. E Block Chair of Cancer Research, Department of Internal Medicine, University of Iowa. Dr Burkard is a medical oncologist who specializes in the treatment of breast cancer and in precision oncology

Biography
Alex's focus at Khosla Ventures is in biotechnology, healthcare, data science, and A IML.

Talk

Emerging Therapeutics Showcase:
Neosplice Therapeutics

Biography
John Quackenbush is Professor of Computational Biology and Bioinformatics in the Department of Biostatistics at the Harvard T. H. Chan School of Public Health. Trained in theoretical physics, he transitioned to genomics through a Human Genome Project fellowship, with subsequent appointments at the Salk Institute, Stanford University, and The Institute for Genomic Research, before joining Harvard in 2005. His research leverages biological data to understand how many small genetic effects combine to influence health and disease. Central to his work is modeling gene regulatory networks and characterizing how these networks vary across health states, by sex and gender, and between individuals. He has over 350 publications with more than 105,000 citations, and his Net Zoo software tools are used. His honors include being named a White House Open Science Champion of Change (2013) and being elected to the National Academy of Medicine in 2022. He founded Genospace in 2012, which was acquired in 2017.

Talk
Target Discovery: Beyond Genomics - Revealing Hidden Layers of Biology with AI

Biography
Dr Muzzey is CSO of Myriad Genetics, a leader in genetic testing and precision medicine. Before joining Myriad, he was a postdoctoral scholar at University of California, San Francisco, with a fellowship from the Damon Runyon Cancer Research Foundation. Dr. Muzzey received a B. A. with honors in Biochemical Sciences from Harvard University and a Ph. D. in Biophysics from Harvard University.

Biography
Lalin Theverapperuma, PhD, is founder and CEO of Expert Intelligence. Lalin created Limited Sample Models(LSM), a governed AI approach designed for high stakes scientific environments where data is limited and decisions must be auditable. The approach combines deep diffusion learning with expert in the loop guidance to deliver high accuracy decisions with calibrated uncertainty and full traceability. Before founding Expert Intelligence, Lalin led ML and DSP for Apple iPhone and AirPod and later led hybrid ML initiatives for AR and VR at Meta.

Talk
Precision medicine reveals a hard truth: large, foundational AI models do not solve pharma’s hardest problems. In regulated, data-scarce settings, they fail validation and create rework. This talk presents Limited Sample Models, a production-proven approach for high-accuracy, audit-ready AI that enables defensible decisions across biopharma and clinical workflows.